Abstracts tagged "Opioids and osteoarthritis"

Abstract Number: 1133 • 2018 ACR/ARHP Annual Meeting
Factors for Opioids Use in the Early Treatment Options for the Knee Osteoarthritis Patients
Soo-Kyung Cho¹, Seongmi Choi², Seul Gi Im², Hyoungyoung Kim¹, Sun-Young Jung³, Eun Jin Jang⁴ and Yoon-Kyoung Sung⁵, ¹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Statistics, Kyungpook National University, Daegu, Korea, Republic of (South), ³College of Pharmacy, Chung-Ang University, Seoul, Korea, Republic of (South), ⁴Information Statistics, Andong National University, Andong-si, Korea, Republic of (South), ⁵Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)
Background/Purpose: Current guidelines for osteoarthritis (OA) treatment recommend a range of nonpharmacological and pharmacological interventions to alleviate pain, improve function and quality of life. Most…
Abstract Number: 952 • 2015 ACR/ARHP Annual Meeting
Cost-Effectiveness of Opioids for the Treatment of Knee Osteoarthritis: Impact of Chronic Opioid Use on Total Knee Arthroplasty Outcomes
Savannah R. Smith¹, Jeffrey N. Katz², Jamie E. Collins³ and Elena Losina⁴, ¹Orthopedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopedic Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Orthopedics, Brigham and Women's Hospital, BU School of Public Health and Harvard Medical School, Boston, MA
Background/Purpose: The US spends over $1 billion annually on opioids for persons with knee OA. We evaluated whether the use of opioids offers good value…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].